FS-8002
/ Huapu Bio
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
March 26, 2025
FS-8002, a bifunctional antibody fusion protein of anti-VEGF and anti-TGF-β, exhibits significant anti-tumor activity in preclinical studies
(AACR 2025)
- "FS-8002 exhibited significant anti-tumor effect in two "cold tumor" xenograft models (human PBMC reconstituted MDA-MB-231 model and HT-29 cells model) as single agent or in combination with anti-PD-1 antibody (Keytruda®). All the preclinical data supported FS-8002 to be studied in clinical trials."
Preclinical • Oncology • TGFB1
April 09, 2025
Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacokinetics, and Preliminary Efficacy of FS-8002
(clinicaltrials.gov)
- P1 | N=54 | Recruiting | Sponsor: Shanghai Pushi Medical Science Co. Ltd | Not yet recruiting ➔ Recruiting | N=86 ➔ 54
Enrollment change • Enrollment open • Oncology • Solid Tumor
1 to 2
Of
2
Go to page
1